133 related articles for article (PubMed ID: 37937786)
1. Anti-BNLF2b Screening for Nasopharyngeal Cancer.
Yan K
N Engl J Med; 2023 Nov; 389(19):1824. PubMed ID: 37937786
[No Abstract] [Full Text] [Related]
2. Anti-BNLF2b Screening for Nasopharyngeal Cancer.
Ren T
N Engl J Med; 2023 Nov; 389(19):1824-1825. PubMed ID: 37937787
[No Abstract] [Full Text] [Related]
3. Anti-BNLF2b Screening for Nasopharyngeal Cancer. Reply.
Li T; Ji M; Xia N
N Engl J Med; 2023 Nov; 389(19):1825. PubMed ID: 37937788
[No Abstract] [Full Text] [Related]
4. Nasopharyngeal cancer screening with an anti-BNLF2b antibody: a new arrow in the quiver?
Lam WKJ; Chan ATC
Nat Rev Clin Oncol; 2024 Jan; 21(1):6-7. PubMed ID: 37794170
[No Abstract] [Full Text] [Related]
5. Ambient Temperature and Screening for Nasopharyngeal Cancer.
Chan KCA; Chu SWI; Lo YMD
N Engl J Med; 2018 Mar; 378(10):962-963. PubMed ID: 29514031
[No Abstract] [Full Text] [Related]
6. Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma.
Jiang C; Chen J; Xie S; Zhang L; Xiang Y; Lung M; Kam NW; Kwong DL; Cao S; Guan XY
Int J Cancer; 2018 Dec; 143(12):3209-3217. PubMed ID: 29971780
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China.
Chen H; Chen S; Lu J; Wang X; Li J; Li L; Fu J; Scheper T; Meyer W; Peng YH; Liu W
Cancer Prev Res (Phila); 2017 Sep; 10(9):542-550. PubMed ID: 28754665
[TBL] [Abstract][Full Text] [Related]
8. Screening for nasopharyngeal cancer.
Yang S; Wu S; Zhou J; Chen XY
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008423. PubMed ID: 26544798
[TBL] [Abstract][Full Text] [Related]
9. Screening for Nasopharyngeal Cancer in High-Risk Populations: A Small Price to Pay for Early Disease Identification?
de Almeida JR; Bratman SV; Hansen AR
J Natl Cancer Inst; 2021 Jul; 113(7):803-804. PubMed ID: 33351096
[No Abstract] [Full Text] [Related]
10. [Cost-effectiveness evaluation of seven screening strategies for nasopharyngeal carcinoma].
Rao DP; Liu Q; Cao SM
Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):549-53. PubMed ID: 22967476
[TBL] [Abstract][Full Text] [Related]
11. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer.
Chan KCA; Woo JKS; King A; Zee BCY; Lam WKJ; Chan SL; Chu SWI; Mak C; Tse IOL; Leung SYM; Chan G; Hui EP; Ma BBY; Chiu RWK; Leung SF; van Hasselt AC; Chan ATC; Lo YMD
N Engl J Med; 2017 Aug; 377(6):513-522. PubMed ID: 28792880
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions.
Lam WKJ; King AD; Miller JA; Liu Z; Yu KJ; Chua MLK; Ma BBY; Chen MY; Pinsky BA; Lou PJ; Woo JKS; Hsu WL; Simon J; Doolan DL; Waterboer T; Hui EP; Li H; Tsang RK; Wong KCW; Goh JP; Vlantis AC; Ai QY; Wong LM; Abdullah V; Lin JC; Chen CJ; Pfeiffer RM; Le QT; Lee AWM; Ji M; Cao S; Ma J; Chan ATC; Chan KCA; Hildesheim A
J Natl Cancer Inst; 2023 Apr; 115(4):355-364. PubMed ID: 36723440
[TBL] [Abstract][Full Text] [Related]
14. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
15. Liu et al. respond to "Epstein-Barr virus screening for nasopharyngeal carcinoma".
Liu Z; Ye W; Zeng YX; Cao SM
Am J Epidemiol; 2013 Feb; 177(3):254-5. PubMed ID: 23255782
[No Abstract] [Full Text] [Related]
16. Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.
Baizig NM; Morand P; Seigneurin JM; Boussen H; Fourati A; Gritli S; Oueslati Z; Touati S; Gamoudi A; Ben Abdallah M; El May M; El May A
Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1005-11. PubMed ID: 21805179
[TBL] [Abstract][Full Text] [Related]
17. A comparison of EBV serology and serum cell-free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohort.
Tay JK; Siow CH; Goh HL; Lim CM; Hsu PP; Chan SH; Loh KS
Int J Cancer; 2020 May; 146(10):2923-2931. PubMed ID: 31705522
[TBL] [Abstract][Full Text] [Related]
18. [Research of nasopharyngeal carcinoma and the applicationof epstein-barr virus immediate early protein].
Zhao XX; Zhang LC
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jul; 30(13):1078-1083. PubMed ID: 29798044
[TBL] [Abstract][Full Text] [Related]
19. Screening for nasopharyngeal carcinoma.
Lancet; 1984 Jul; 2(8393):20-2. PubMed ID: 6145937
[No Abstract] [Full Text] [Related]
20. Plasma Epstein-Barr virus (EBV) DNA: role as a screening test for nasopharyngeal carcinoma (NPC)?
Wong LP; Lai KT; Tsui E; Kwong KH; Tsang RH; Ma ES
Int J Cancer; 2005 Nov; 117(3):515-6. PubMed ID: 15906350
[No Abstract] [Full Text] [Related]
[Next] [New Search]
